NovoCure Stock Price, News & Analysis (NASDAQ:NVCR) $12.50 +0.23 (+1.87%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$11.76▼$12.5550-Day Range$11.13▼$17.3452-Week Range$10.87▼$120.03Volume1.26 million shsAverage Volume1.32 million shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice Target$45.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability NovoCure MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside262.3% Upside$45.29 Price TargetShort InterestHealthy8.68% of Float Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment0.13Based on 23 Articles This WeekInsider TradingSelling Shares$4,832 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.04) to ($1.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector466th out of 951 stocksSurgical & Medical Instruments Industry52nd out of 93 stocks 3.3 Analyst's Opinion Consensus RatingNovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.29, NovoCure has a forecasted upside of 262.3% from its current price of $12.50.Amount of Analyst CoverageNovoCure has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.68% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in NovoCure has recently decreased by 6.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.Environmental SustainabilityThe Environmental Impact score for NovoCure is -1.15. Previous Next 1.7 News and Social Media Coverage News SentimentNovoCure has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for NovoCure this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for NVCR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,832.00 in company stock.Percentage Held by InsidersOnly 5.67% of the stock of NovoCure is held by insiders.Percentage Held by Institutions84.11% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NovoCure are expected to grow in the coming year, from ($2.04) to ($1.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NovoCure Stock (NASDAQ:NVCR)NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Read More NVCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCR Stock News HeadlinesDecember 2, 2023 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Moderate Buy" from BrokeragesDecember 2, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for NovoCure Limited's FY2023 Earnings (NASDAQ:NVCR)December 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 2, 2023 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) to Post FY2023 Earnings of ($2.01) Per Share, HC Wainwright ForecastsDecember 1, 2023 | markets.businessinsider.comBuy Rating on NovoCure Amid Strategic Restructuring and Promising Clinical TrialsDecember 1, 2023 | americanbankingnews.comNovoCure Limited Expected to Post Q2 2024 Earnings of ($0.48) Per Share (NASDAQ:NVCR)December 1, 2023 | americanbankingnews.comNovoCure Limited Forecasted to Earn Q3 2024 Earnings of ($0.45) Per Share (NASDAQ:NVCR)November 29, 2023 | americanbankingnews.comSintx Technologies (NASDAQ:SINT) & NovoCure (NASDAQ:NVCR) Head-To-Head SurveyDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 28, 2023 | marketwatch.comNovocure to Cut 13% of Workforce in RestructuringNovember 28, 2023 | markets.businessinsider.comNovocure To Reduce 13% Of Current Workforce - Quick FactsNovember 28, 2023 | msn.comNovocure to eliminate 13% of workforce in restructuring effortNovember 21, 2023 | finance.yahoo.comNovocure to Participate in 35th Annual Piper Sandler Healthcare ConferenceNovember 16, 2023 | seekingalpha.comNovoCure: Significant Upside Even Without A BreakthroughNovember 16, 2023 | finance.yahoo.comNovoCure Limited (NASDAQ:NVCR) institutional owners may be pleased with recent gains after 85% loss over the past yearNovember 3, 2023 | finance.yahoo.comIs Novocure Stock a Buy?October 30, 2023 | finance.yahoo.comThe NovoCure Ltd (NVCR) Company: A Short SWOT AnalysisOctober 28, 2023 | finance.yahoo.comNovoCure Limited (NASDAQ:NVCR) Q3 2023 Earnings Call TranscriptOctober 28, 2023 | markets.businessinsider.comNovoCure Earns Buy Rating Amid Promising Pipeline and Operational EfficiencyOctober 27, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on NovoCure (NVCR)October 26, 2023 | finance.yahoo.comWhy Novocure Stock Was Sick TodayOctober 26, 2023 | finance.yahoo.comNovoCure Ltd (NVCR) Reports Q3 2023 Financial ResultsOctober 26, 2023 | finance.yahoo.comNovoCure (NVCR) Q3 2023 Earnings Call TranscriptOctober 26, 2023 | seekingalpha.comNovoCure Limited 2023 Q3 - Results - Earnings Call PresentationOctober 26, 2023 | finance.yahoo.comNovocure Reports Third Quarter 2023 Financial ResultsOctober 15, 2023 | finance.yahoo.comNovocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023October 12, 2023 | finance.yahoo.comNovocure and Stanford School of Medicine to Establish Tumor Treating Fields Research ProgramSee More Headlines Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/26/2023Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCR CUSIPN/A CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,320Year FoundedN/APrice Target and Rating Average Stock Price Target$45.29 High Stock Price Target$51.00 Low Stock Price Target$25.00 Potential Upside/Downside+262.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,530,000.00 Net Margins-39.14% Pretax Margin-36.86% Return on Equity-46.89% Return on Assets-16.89% Debt Debt-to-Equity Ratio1.44 Current Ratio6.67 Quick Ratio6.43 Sales & Book Value Annual Sales$537.84 million Price / Sales2.48 Cash FlowN/A Price / Cash FlowN/A Book Value$3.68 per share Price / Book3.40Miscellaneous Outstanding Shares106,860,000Free Float100,802,000Market Cap$1.34 billion OptionableOptionable Beta0.52 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. William F. Doyle (Age 61)Executive Chairman Comp: $1.52MMr. Asaf Danziger (Age 57)President, CEO & Director Comp: $1.7MMs. Ashley Cordova (Age 43)Chief Financial Officer Comp: $933.39kMr. Wilhelmus C. M. Groenhuysen (Age 65)Chief Operating Officer Comp: $1.01MMr. Pritesh Shah (Age 44)Chief Growth Officer Comp: $810.6kMr. Frank LeonardPresident of CNS Cancers U.S.Prof. Yoram Palti M.D. (Age 85)Ph.D., Founder & CTO Comp: $282.51kDr. Moshe Giladi Ph.D.Chief Science OfficerMs. Ingrid GoldbergVP of Investor RelationsMr. Barak Ben Arye (Age 47)General Counsel More ExecutivesKey CompetitorsTandem Diabetes CareNASDAQ:TNDMLeMaitre VascularNASDAQ:LMATAlphatecNASDAQ:ATECEmbectaNASDAQ:EMBCMiMedx GroupNASDAQ:MDXGView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 824 shares on 12/1/2023Ownership: 0.069%Banque Pictet & Cie SASold 20,805 shares on 11/27/2023Ownership: 0.035%Deutsche Bank AGSold 115,555 shares on 11/24/2023Ownership: 0.013%Walleye Capital LLCBought 1,900 shares on 11/21/2023Ownership: 0.000%Walleye Trading LLCBought 2,200 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions NVCR Stock Analysis - Frequently Asked Questions Should I buy or sell NovoCure stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVCR shares. View NVCR analyst ratings or view top-rated stocks. What is NovoCure's stock price target for 2024? 8 equities research analysts have issued 1-year target prices for NovoCure's stock. Their NVCR share price targets range from $25.00 to $51.00. On average, they predict the company's share price to reach $45.29 in the next twelve months. This suggests a possible upside of 262.3% from the stock's current price. View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts. How have NVCR shares performed in 2023? NovoCure's stock was trading at $73.35 at the start of the year. Since then, NVCR stock has decreased by 83.0% and is now trading at $12.50. View the best growth stocks for 2023 here. When is NovoCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our NVCR earnings forecast. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) released its earnings results on Thursday, October, 26th. The medical equipment provider reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.05. The medical equipment provider had revenue of $127.30 million for the quarter, compared to analysts' expectations of $128.75 million. NovoCure had a negative trailing twelve-month return on equity of 46.89% and a negative net margin of 39.14%. The firm's revenue for the quarter was down 2.8% on a year-over-year basis. During the same period last year, the firm posted ($0.25) earnings per share. What ETFs hold NovoCure's stock? ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ), VanEck Israel ETF (ISRA), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Medical Devices ETF (IHI).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What is Asaf Danziger's approval rating as NovoCure's CEO? 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ). Who are NovoCure's major shareholders? NovoCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), Baillie Gifford & Co. (6.38%), Morgan Stanley (1.02%), Palo Alto Investors LP (0.62%), Charles Schwab Investment Management Inc. (0.51%) and Northern Trust Corp (0.41%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NVCR) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.